WATER IV Prostate Cancer

Running, not enrolling · Not applicable

Conditions studied: Localized Prostate Cancer

In brief

This is a multicenter, prospective, randomized clinical trial that aims to assess the safety and efficacy of Aquablation Therapy in men with low-risk to intermediate to high-risk localized prostate cancer who are candidates for, or have opted for, prostatectomy. Participants will be randomized to either Aquablation Therapy or radical prostatectomy and followed up to 10 years.

Key facts

Study ID

NCT06651632

Run by

PROCEPT BioRobotics

People needed

280

Starts

2025-02-03

Expected to finish

2037-01-01

Last updated by the study team

2026-05-04

Who can join

Age: 45 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Biological male with age ≥ 45 years at the time of consent
• Biopsy positive Grade Group 1-3 prostate cancer
• Are candidates for prostatectomy or, in the case of GG1 disease, have already selected a radical therapy as their treatment.
• Clinical Stage ≤ T2c
• PSA ≤ 20 ng/ml
• Prostate volume ≥25 ml

You may not qualify if…

• Any prior or current local or systemic treatment for prostate cancer, including but not limited to surgery, radiation therapy (external or brachytherapy), tissue ablation, hormone therapy or chemotherapy.
• Patients with previous surgical or minimally invasive treatment of benign prostatic hyperplasia within the prior 3 months of study treatment.
• Evidence of lymph node, bone metastasis, extracapsular extension or seminal vesicle invasion.
• Patient is unwilling to accept a blood transfusion if required.
• Any condition or history of illness or surgery that may pose an additional risk to patients undergoing the Aquablation or radical prostatectomy procedure such as:
• 5a. Medical conditions that preclude the use of anesthesia; 5b. Any condition or history of active rectal inflammatory bowel disease or other factors which might increase the risk of rectal injury (i.e. fistula formation); 5c. Patient is unable to stop anticoagulants or antiplatelet agents prior to study treatment per standard of care; 5d. Any other condition or history of infection, illness or surgery that in the opinion of the investigator might affect the outcome of the study procedure, study conduct, and study results; or pose additional risks to the patient (e.g., other cancer, active urethral stricture disease).
• Patients who are unable to provide informed consent due to cognitive impairment, legal status (such as incarceration), or other factors limiting autonomy or unwilling or unable to follow study instructions including randomization and complete all required study visits through 10 years. This includes individuals with severe cognitive disabilities, those under legal guardianship, or those currently incarcerated.
• Patient currently participating in other studies unless approved by Sponsor in writing.

Where it is running

• Arizona State Urological Institute — Chandler, Arizona, United States
• East Valley Urology Center — Mesa, Arizona, United States
• University of Southern California — Los Angeles, California, United States
• Boulder Medical Center — Boulder, Colorado, United States
• Advanced Research — Delray Beach, Florida, United States
• University of Miami — Miami, Florida, United States
• Florida Urology Partners — Tampa, Florida, United States
• Trophy Point Urology — Tampa, Florida, United States
• Georgia Urology — Atlanta, Georgia, United States
• Mountain View Hospital — Idaho Falls, Idaho, United States
• University of Chicago — Chicago, Illinois, United States
• Endeavor Health — Glenview, Illinois, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Kansas City Urology Care — North Kansas City, Missouri, United States
• Kearney Urology Center — Kearney, Nebraska, United States
• Adult & Pediatric Urology — Omaha, Nebraska, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Integrated Medical Professionals, PLLC — New York, New York, United States
• University of Rochester Medical Center — Rochester, New York, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States
• MUSC Hollings Cancer Center — Charleston, South Carolina, United States
• Tidelands Health Urology — Murrells Inlet, South Carolina, United States
• Urology Austin — Austin, Texas, United States
• Urology Clinics of North Texas — Dallas, Texas, United States
• Potomac Urology — Alexandria, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.